Tag Archives: Cantor Fitzgerald

Cantor Fitzgerald Sidelined on Humana Ahead of Merger Ruling

Joseph France, a five-star rated analyst from Cantor Fitzgerald has reiterated his hold rating for health insurance company Humana Inc (NYSE: HUM) ahead of the ruling on its proposed $37 billion merger with Aetna Inc (NYSE: AET). “We are… tweaking

Radius Health Inc (RDUS) Remains a Buy After Positive Data of RAD1901 Study

Analyst Mara Goldstein from Cantor Fitzgerald reiterated a Buy rating on the development-stage biopharmaceutical company, Radius Health Inc. (NASDAQ: RDUS), in a note to investors yesterday. Goldsein set a price target of $70, which represents a 48.71% upside from the stock’s

Analyst Comments Following A Record Breaking “Singles Day” for Alibaba Group (BABA)

Chinese e-commerce giant Alibaba Group Holding (NYSE: BABA) raked in $17.8 billion (120.7 billion CNY) during its annual Singles’ Day (Guanggun Jie) sales this year, indicating resiliency in the Chinese consumers. Cantor Fitzgerald analyst Youssef Squali weighed in on the

Ahead of Earnings, Yelp (YELP) is Still a Buy Despite Google’s Possum Update

Amidst the furor surrounding its M&A chatter, popular business review site Yelp Inc. (NYSE: YELP) is all set to announce its 3Q16 results this Wednesday. YELP had recently taken a hit to its site traffic after Google’s algorithm change (Possum)

Analysts Anticipate Strong 3Q16 Results for Facebook (FB)

Facebook’s (NASDAQ: FB) earnings are expected to be announced tomorrow Nov 2. Facebook showed quite a nice performance lately, closing on to its 52-week high of $133.50 despite the burgeoning Snapchat threat and a general slump in the US market. Facebook

Twitter (TWTR): Poised to Fly High Or Time for Last Rites?

Twitter Inc (NYSE: TWTR) seems to be taking a lot of heat lately. The workforce layoffs, takeover rumors, better-than-feared 3Q16 results, presidential campaign, speculations about CEO, monetization challenges, and sales force restructuring are just a few things happening in tandem at TWTR